BECHEM: A Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies


Hematologic Disorders : Relapsed or refractory hematologic malignancies


This study is done for leukemia or lymphoma that has relapsed (come back) or is refractory (unresponsive) and strong chemotherapy (anti-cancer drugs) (called re-induction treatment) is needed. Re-induction treatment is given in an attempt to bring the disease back into remission (no signs or symptoms of leukemia or lymphoma).

There is no “standard” therapy for recurrent leukemia or lymphoma. Most commonly used treatment plans have drugs similar to those used in this protocol, although the drugs may be given in different combinations and on different schedules.

Researchers want to know if adding a new drug, called Bendamustine will be safe and possible to give with other re-induction chemotherapy drugs.


Eligibility criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Sima Jeha, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.